Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 85 articles:
HTML format



Single Articles


    March 2021
  1. HUSSAIN M, Desai C, de Bono J
    Olaparib in Metastatic Castration-Resistant Prostate Cancer. Reply.
    N Engl J Med. 2021;384:1175-1176.
    PubMed    


  2. SMITH TJ
    Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021;384:1175.
    PubMed    


  3. BISWAS B, Ganguly S, Ghosh J
    Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021;384:1174-1175.
    PubMed    


  4. MCCAW ZR, Liu MA, Wei LJ
    Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021;384:1174.
    PubMed    


    December 2020
  5. ARAP W, Pasqualini R, Costello JF
    Prostate Cancer Progression and the Epigenome.
    N Engl J Med. 2020;383:2287-2290.
    PubMed    


    September 2020
  6. SHOAG JE, Nyame YA, Hu JC
    Reconsidering the Trade-offs of Prostate Cancer Screening. Reply.
    N Engl J Med. 2020;383:1290.
    PubMed    


  7. WITTMANN D, Skolarus T, Glode LM
    Reconsidering the Trade-offs of Prostate Cancer Screening.
    N Engl J Med. 2020;383:1289-1290.
    PubMed    


  8. HUSSAIN M, Mateo J, Fizazi K, Saad F, et al
    Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020 Sep 20. doi: 10.1056/NEJMoa2022485.
    PubMed     Abstract available


  9. MAHAL BA, Alshalalfa M, Kensler KH, Chowdhury-Paulino I, et al
    Racial Differences in Genomic Profiling of Prostate Cancer.
    N Engl J Med. 2020;383:1083-1085.
    PubMed    


  10. FIZAZI K, Shore N, Tammela TL, Ulys A, et al
    Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
    N Engl J Med. 2020;383:1040-1049.
    PubMed     Abstract available


    August 2020
  11. DE BONO J, Kang J, Hussain M
    Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply.
    N Engl J Med. 2020;383:891.
    PubMed    


  12. HEIDEGGER I, Pircher A
    Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020;383:890-891.
    PubMed    


  13. MUTETWA T, Foulkes WD, Polak P
    Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020;383:890.
    PubMed    


    June 2020
  14. SHOAG JE, Nyame YA, Gulati R, Etzioni R, et al
    Reconsidering the Trade-offs of Prostate Cancer Screening.
    N Engl J Med. 2020;382:2465-2468.
    PubMed    


  15. AHDOOT M, Turkbey B, Pinto P
    Biopsy for Prostate Cancer Diagnosis. Reply.
    N Engl J Med. 2020;382:2271.
    PubMed    


  16. STANZIONE A, Imbriaco M, Cuocolo R
    Biopsy for Prostate Cancer Diagnosis.
    N Engl J Med. 2020;382:2270-2271.
    PubMed    


  17. SCHOLZ M, Lam R, Turner J
    Biopsy for Prostate Cancer Diagnosis.
    N Engl J Med. 2020;382:2270.
    PubMed    


    May 2020
  18. HIGANO CS
    Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMe2016433.
    PubMed    


  19. STERNBERG CN, Fizazi K, Saad F, Shore ND, et al
    Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMoa2003892.
    PubMed     Abstract available


  20. SHORE ND, Saad F, Cookson MS, George DJ, et al
    Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMoa2004325.
    PubMed     Abstract available


    April 2020
  21. DE BONO J, Mateo J, Fizazi K, Saad F, et al
    Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020 Apr 28. doi: 10.1056/NEJMoa1911440.
    PubMed     Abstract available


  22. WELCH HG, Albertsen PC
    Reconsidering Prostate Cancer Mortality - The Future of PSA Screening.
    N Engl J Med. 2020;382:1557-1563.
    PubMed    


    March 2020
  23. DE WIT R, de Bono J, Castellano D
    Cabazitaxel in Metastatic Prostate Cancer. Reply.
    N Engl J Med. 2020;382:1286.
    PubMed    


  24. DI NUNNO V, Mollica V, Massari F
    Cabazitaxel in Metastatic Prostate Cancer.
    N Engl J Med. 2020;382:1286.
    PubMed    


  25. AHDOOT M, Wilbur AR, Reese SE, Lebastchi AH, et al
    MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    N Engl J Med. 2020;382:917-928.
    PubMed     Abstract available


    December 2019
  26. AL HUSSEIN AL AWAMLH B, Ma X, Christos P, Hu JC, et al
    Active Surveillance for Black Men with Low-Risk Prostate Cancer in the United States.
    N Engl J Med. 2019;381:2581-2582.
    PubMed    


  27. EISENBERGER MA, Antonarakis ES
    Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer - Playing the Right CARD.
    N Engl J Med. 2019;381:2564-2566.
    PubMed    


    October 2019
  28. DAVIS ID, Stockler MR, Sweeney CJ
    Enzalutamide in Metastatic Prostate Cancer. Reply.
    N Engl J Med. 2019;381:1494-1495.
    PubMed    


  29. LEVEQUE D
    Enzalutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2019;381:1494.
    PubMed    


  30. YIN M, Vinh-Hung V, Verschraegen C
    Enzalutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2019;381:1493-1494.
    PubMed    


  31. VARKARIS A, Bubley G
    Enzalutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2019;381:1493.
    PubMed    


    September 2019
  32. DE WIT R, de Bono J, Sternberg CN, Fizazi K, et al
    Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2019 Sep 30. doi: 10.1056/NEJMoa1911206.
    PubMed     Abstract available


  33. ARONOWITZ R, Greene JA
    Contingent Knowledge and Looping Effects - A 66-Year-Old Man with PSA-Detected Prostate Cancer and Regrets.
    N Engl J Med. 2019;381:1093-1096.
    PubMed    


    July 2019
  34. TANNOCK IF
    Improving Treatment for Advanced Prostate Cancer.
    N Engl J Med. 2019;381:176-177.
    PubMed    


  35. KLOTZ L
    Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer.
    N Engl J Med. 2019;381:84-86.
    PubMed    


    June 2019
  36. DAVIS ID, Martin AJ, Stockler MR, Begbie S, et al
    Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
    N Engl J Med. 2019 Jun 2. doi: 10.1056/NEJMoa1903835.
    PubMed     Abstract available


    May 2019
  37. CHI KN, Agarwal N, Bjartell A, Chung BH, et al
    Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    N Engl J Med. 2019 May 31. doi: 10.1056/NEJMoa1903307.
    PubMed     Abstract available


  38. BUTLER S, Muralidhar V, Chavez J, Fullerton Z, et al
    Active Surveillance for Low-Risk Prostate Cancer in Black Patients.
    N Engl J Med. 2019;380:2070-2072.
    PubMed    


  39. GOODMAN PJ, Tangen CM, Thompson IM Jr
    More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply.
    N Engl J Med. 2019;380:e38.
    PubMed    


  40. GARNICK MB
    More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
    N Engl J Med. 2019;380:e38.
    PubMed    


  41. STAPFF MP, Palm S
    More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
    N Engl J Med. 2019;380:e38.
    PubMed    


    March 2019
  42. BILL-AXELSON A, Holmberg L, Garmo H
    Radical Surgery or Watchful Waiting in Prostate Cancer. Reply.
    N Engl J Med. 2019;380:1084.
    PubMed    


  43. CHARKES ND
    Radical Surgery or Watchful Waiting in Prostate Cancer.
    N Engl J Med. 2019;380:1084.
    PubMed    


  44. YANG Z, McCaw ZR, Yin G
    Radical Surgery or Watchful Waiting in Prostate Cancer.
    N Engl J Med. 2019;380:1083-1084.
    PubMed    


    February 2019
  45. FIZAZI K, Shore N, Tammela TL, Ulys A, et al
    Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2019 Feb 14. doi: 10.1056/NEJMoa1815671.
    PubMed     Abstract available


    January 2019
  46. GOODMAN PJ, Tangen CM, Darke AK, Lucia MS, et al
    Long-Term Effects of Finasteride on Prostate Cancer Mortality.
    N Engl J Med. 2019;380:393-394.
    PubMed    


    December 2018
  47. BILL-AXELSON A, Holmberg L, Garmo H, Taari K, et al
    Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.
    N Engl J Med. 2018;379:2319-2329.
    PubMed     Abstract available


    October 2018

  48. Enzalutamide in Castration-Resistant Prostate Cancer.
    N Engl J Med. 2018;379:1380-1381.
    PubMed    


  49. BREGNI G, Rebuzzi SE, Fornarini G
    Enzalutamide in Castration-Resistant Prostate Cancer.
    N Engl J Med. 2018;379:1380-1.
    PubMed    


  50. ANKER MS, Lehmann LH, Ander SD
    Enzalutamide in Castration-Resistant Prostate Cancer.
    N Engl J Med. 2018;379:1380.
    PubMed    


    September 2018
  51. VEDULA R, Vaidya A, Galetta K, Laubach J, et al
    A Sticky Situation.
    N Engl J Med. 2018;379:e22.
    PubMed    


  52. ANTONARAKIS ES
    Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.
    N Engl J Med. 2018;379:1087-1089.
    PubMed    


    August 2018
  53. VICKERS A, Ehdaie B
    MRI-Targeted Biopsy for Prostate-Cancer Diagnosis.
    N Engl J Med. 2018;379:589.
    PubMed    


  54. MARTINI A, Cumarasamy S, Tewari AK
    MRI-Targeted Biopsy for Prostate-Cancer Diagnosis.
    N Engl J Med. 2018;379:589.
    PubMed    



  55. MRI-Targeted Biopsy for Prostate-Cancer Diagnosis.
    N Engl J Med. 2018;379:589-590.
    PubMed    


    June 2018
  56. RACHNER TD, Tsourdi E, Hofbauer LC
    Apalutamide and Metastasis-free Survival in Prostate Cancer.
    N Engl J Med. 2018;378:2541-2.
    PubMed    



  57. Apalutamide and Metastasis-free Survival in Prostate Cancer.
    N Engl J Med. 2018;378:2541-2542.
    PubMed    


  58. HUSSAIN M, Fizazi K, Saad F, Rathenborg P, et al
    Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2018;378:2465-2474.
    PubMed     Abstract available


  59. BEAVER JA, Kluetz PG, Pazdur R
    Metastasis-free Survival - A New End Point in Prostate Cancer Trials.
    N Engl J Med. 2018;378:2458-2460.
    PubMed    


  60. SMITH MR
    Progress in Nonmetastatic Prostate Cancer.
    N Engl J Med. 2018;378:2531-2532.
    PubMed    


    May 2018
  61. BARRY MJ, Rosenkrantz AB
    MRI-Targeted versus Ultrasonography-Guided Biopsy for Suspected Prostate Cancer.
    N Engl J Med. 2018;378:1835-1836.
    PubMed    


  62. SMITH TJ, Loprinzi CL, Deville C
    Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.
    N Engl J Med. 2018;378:1745-1746.
    PubMed    


    April 2018
  63. RODRIGUEZMORENO JF, GarciaDonas J
    Metastatic Prostate Cancer.
    N Engl J Med. 2018;378:1653.
    PubMed    


  64. ABATE-SHEN C
    Prostate Cancer Metastasis - Fueled by Fat?
    N Engl J Med. 2018;378:1643-1645.
    PubMed    



  65. Metastatic Prostate Cancer.
    N Engl J Med. 2018;378:1653-1654.
    PubMed    


    March 2018
  66. KASIVISVANATHAN V, Rannikko AS, Borghi M, Panebianco V, et al
    MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
    N Engl J Med. 2018 Mar 18. doi: 10.1056/NEJMoa1801993.
    PubMed     Abstract available


    February 2018
  67. CHEN D, Ayala GE
    Innervating Prostate Cancer.
    N Engl J Med. 2018;378:675-677.
    PubMed    


  68. SMITH MR, Saad F, Chowdhury S, Oudard S, et al
    Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    N Engl J Med. 2018 Feb 8. doi: 10.1056/NEJMoa1715546.
    PubMed     Abstract available


  69. SARTOR O, de Bono JS
    Metastatic Prostate Cancer.
    N Engl J Med. 2018 Feb 7. doi: 10.1056/NEJMra1701695.
    PubMed    


    October 2017
  70. FIZAZI K, Chi KN
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1697-8.
    PubMed    


  71. ISMAILI N, Guessous F
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1695-6.
    PubMed    


  72. TANNOCK IF
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1695.
    PubMed    


  73. DE BONO J, Eisenberger M, Sartor O
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1694-5.
    PubMed    


  74. JAMES ND, Spears MR, Sydes MR
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1696-7.
    PubMed    


    September 2017
  75. SHARMA V, Karnes RJ
    Prostatectomy versus Observation for Early Prostate Cancer.
    N Engl J Med. 2017;377:1302.
    PubMed    



  76. Prostatectomy versus Observation for Early Prostate Cancer.
    N Engl J Med. 2017;377:1301-1303.
    PubMed    


  77. WALLIS CJD, Klotz L
    Prostatectomy versus Observation for Early Prostate Cancer.
    N Engl J Med. 2017;377:1301-2.
    PubMed    


    July 2017
  78. LOGOTHETIS CJ
    Improved Outcomes in Men with Advanced Prostate Cancer.
    N Engl J Med. 2017;377:388-390.
    PubMed    


  79. HAYMART MR, Miller DC, Hawley ST
    Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment?
    N Engl J Med. 2017;377:203-206.
    PubMed    


  80. WILT TJ, Jones KM, Barry MJ, Andriole GL, et al
    Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.
    N Engl J Med. 2017;377:132-142.
    PubMed     Abstract available


    June 2017
  81. PINSKY PF, Prorok PC, Kramer BJ
    Prostate Cancer Screening.
    N Engl J Med. 2017;376:2402.
    PubMed    


  82. WALSH PC
    Prostate Cancer Screening.
    N Engl J Med. 2017;376:2401-2.
    PubMed    


  83. FIZAZI K, Tran N, Fein L, Matsubara N, et al
    Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    N Engl J Med. 2017 Jun 4. doi: 10.1056/NEJMoa1704174.
    PubMed     Abstract available


  84. JAMES ND, de Bono JS, Spears MR, Clarke NW, et al
    Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    N Engl J Med. 2017 Jun 3. doi: 10.1056/NEJMoa1702900.
    PubMed     Abstract available


    March 2017
  85. PINSKY PF, Prorok PC, Kramer BS
    Prostate Cancer Screening - A Perspective on the Current State of the Evidence.
    N Engl J Med. 2017;376:1285-1289.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: